research Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
Search
for
Sort by
Research
240-270 / 1000+ results
research Visualizing Severity of Alopecia Tool (SALT) scores in the clinical setting using patient images from a clinical trial
The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.
research When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials
Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
research Repurposing DPP4-Inhibition to Improve Hair Follicle Activation and Regeneration
Blocking DPP4 can potentially speed up hair growth and regeneration, especially after injury or in cases of hair loss.
research Minoxidil
research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
The FDA approved a new Pfizer drug for hair loss in teens.
research Letter in Reply: Alopecia areata after SARS-CoV-2 vaccination
A woman developed alopecia after her second Pfizer vaccine but regrew her hair with treatment and had no issues after a booster shot.
research BH07 The socioeconomic burden of alopecia areata
Alopecia areata causes significant financial strain, especially for women and those with severe symptoms.
research BH23 Mind the gap! Navigating barriers to care access for patients with alopecia areata in the UK: a qualitative interview study
Patients with alopecia areata in the UK face barriers to care, needing better-defined pathways and more education for general practitioners.
research Guest Editor's Note
The supplement aims to improve care for children with alopecia areata.
research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
research First drug for severe alopecia recommended by NICE could benefit 14,000 patients
Ritlecitinib can help about 14,000 people with severe hair loss.
research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
research Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is effective long-term for treating alopecia areata in teens.
research Pantolactams as androgen receptor antagonists for the topical suppression of sebum production
Pfizer found that pantolactam-based compounds can reduce sebum (skin oil) production when applied topically.
research Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production
A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.
research P063 Tracking down autoantibodies
A man developed autoimmune symptoms after the Pfizer COVID-19 vaccine, highlighting the need for thorough vaccine safety checks.
research Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production
Scientists made a chemical (compound 4e) that can be applied on skin to reduce oil production, which can help with acne, but it might cause skin sensitivity to light.
research Ritlecitinib: First Approval
Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
research Hypertrichosis of the eyelashes caused by bimatoprost
Bimatoprost can cause excessive eyelash growth.
research Rational Design and Synthesis of 4-((1R,2R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a Novel, Nonsteroidal Androgen Receptor Antagonist Devoid of Phototoxicity for Dermatological Indications
PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
research A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United States
Alopecia areata affects many in the US, impacting quality of life, with limited treatment options.
research Patient characteristics associated with all-cause healthcare costs of alopecia areata in the United States
Middle-aged patients, those in the Northeast, with comprehensive insurance, extensive hair loss, or additional health issues, and young or older females face higher alopecia areata medical costs.
research Epidemiology, Diagnosis and Management of Alopecia Areata: An Asia‐Pacific Modified Delphi Expert Panel Recommendations
Experts recommend specific treatments for alopecia areata based on age and severity, emphasizing the need for better treatments and acknowledging its psychological impact.
research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
research The 2018 Revision to the Process of Care Model for Evaluation of Erectile Dysfunction
The 2018 update to the ED care model added a new severity score and stressed a detailed evaluation of both physical and psychological aspects.
research NEW GENERATION OF VACCINE TECHNOLOGIES
New vaccine technologies are improving global health by making vaccines more effective and long-lasting.
research New product intros (finasteride/tadalafil (new combination); sutimlimab; human SARS-CoV-2 recombinant nanoparticle vaccine, adjuvanted with AS03; bupropion hydrochloride/dextromethorphan hydrobromide (new combination))
research 032 A multicomponent skin-targeted COVID-19 vaccine elicits robust humoral and cellular immune responses
The new skin-targeted COVID-19 vaccine creates strong immune responses and could improve vaccination methods.
research Tebentafusp-tebn (Kimmtra®)
Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.